Skip to main content
Smart Investors Daily
TV

NASDAQ · TVRD

Tvardi Therapeutics, Inc.

Healthcare · Biotechnology

$1.18

Down-$0.08 (-6.78%)

Updated Nov 17, 2026, 1:19 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
42.12M
P/E ratio
-3.02
Dividend yield
0.00%
52-week range
$0.77 – $5.69
Volume
75.66K
Avg. volume
308.7K

Price performance · TVRD

TVRD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

TVRD closed at $1.18 after 20 trading sessions, up 21.65% for the selected period.

Last close
$1.18
Period change
+21.65%
Period low
$0.79
Period high
$1.41
Daily close
View OHLC price history
TVRD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$1.16$1.18$1.08$1.1875.66K
Nov 12, 2026$1.30$1.30$1.145$1.155167.03K
Nov 11, 2026$1.40$1.61$1.26$1.34459K
Nov 10, 2026$1.39$1.53$1.31$1.41552.32K
Nov 9, 2026$0.96$1.61$0.9577$1.414.59M
Nov 6, 2026$0.8571$0.98$0.8469$0.957855.77K
Nov 5, 2026$0.87$0.882$0.8101$0.8645177.13K
Nov 4, 2026$0.819$0.889$0.8048$0.861450K
Nov 3, 2026$0.83$0.8899$0.7961$0.834993.11K
Nov 2, 2026$0.826$0.85$0.79$0.805394.91K
Oct 30, 2026$0.8677$0.9284$0.7729$0.7928154.88K
Oct 29, 2026$0.89$0.9151$0.85$0.863111.91K
Oct 28, 2026$0.8403$0.9272$0.8403$0.887286.1K
Oct 27, 2026$0.831$0.8998$0.831$0.865372.75K
Oct 26, 2026$0.94$0.97$0.842$0.8421139.58K
Oct 23, 2026$1.0702$1.0702$0.9201$0.94108.87K
Oct 22, 2026$1.01$1.0499$0.9722$0.972255.41K
Oct 21, 2026$1.02$1.09$1.00$1.02137.1K
Oct 20, 2026$1.03$1.0764$0.97$0.992195.19K
Oct 19, 2026$1.01$1.0279$0.9687$0.97201.34K

Latest TVRD news

The latest Smart Investors Daily articles mentioning TVRD.

TVRD research

Overview

Company profile and research snapshot.

Company profile

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.50
Implied upside
—
Analysts
—
TVRD recent ratings
DateFirmRatingTarget
Oct 20, 2026Chardan CapitalBuy—
Jul 30, 2026BTIGBuy—
Jul 8, 2026Raymond JamesOutperform—
Jul 7, 2026BTIGBuy—
Jun 8, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Jul 9, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.